Skip to main content

Table 3 Details of bleeding events

From: Efficacy and safety of rivaroxaban for the treatment of PICC-related upper extremity deep vein thrombosis in cancer patients: a retrospective study

Case

Anticoagulant

Occurred at days of anticoagulation

Tumor type

Bleeding site

1

Nadroparin

137

gastrointestinal

gastrointestinal

2

Nadroparin

64

lymphoma

subcutaneous

3

Rivaroxaban

139

lymphoma

subcutaneous

4

Nadroparin

106

breast

hematuria

5

Rivaroxaban

44

gynecology

hematuria

6

Rivaroxaban

65

gastrointestinal

gastrointestinal

7

Rivaroxaban

61

lung

epistaxis

8

Rivaroxaban

83

breast

hematuria

9

Rivaroxaban

98

breast

subcutaneous

10

Rivaroxaban

181

breast

hematuria

11

Rivaroxaban

63

breast

gastrointestinal

12

Nadroparin

163

breast

gastrointestinal

13

Nadroparin

152

breast

hematuria

14

Rivaroxaban

26

gynecology

gastrointestinal

15

Rivaroxaban

179

gastrointestinal

subcutaneous

16

Nadroparin

110

gynecology

hematuria

17

Rivaroxaban

39

gastrointestinal

epistaxis

18

Rivaroxaban

163

lung

hemoptysis

19

Rivaroxaban

79

lung

hemoptysis